EQS-News

Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical 24.07.2026, 16:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Nova Biomedical / Key word(s): Mergers & Acquisitions/Private Equity
Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical

24.07.2026 / 16:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology.

This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support biopharmaceutical workflows from early development through manufacturing.

NanoCellect® WOLF G2® cell sorting platform introduces gentle, microfluidic-based cell selection and isolation, complementing Nova Biomedical's existing Solentim portfolio for clone generation, verification, and growth analysis. Together, these technologies enable a more integrated approach to cell line development—linking cell selection, single-cell isolation, and high-confidence clone verification.

This expansion of Nova's portfolio will accelerate cell line development timelines and improve clone selection outcomes, while establishing a stronger foundation for process development, scale-up, and manufacturing.

Nova Biomedical's portfolio also includes robust analytical solutions for cell culture monitoring, including metabolite analysis with BioProfile® FLEX2, osmolality measurement with OsmoTECH®, and cell counting and viability with BioProfile® FAST CDV. These capabilities serve as critical control points across the bioprocessing workflow and are used from development through production.

The addition of the NanoCellect products further advances Nova Biomedical's strategy to provide a more connected portfolio of technologies supporting continuity, insight, and decision-making across the full bioprocessing lifecycle.

"NanoCellect adds a critical upstream capability to our portfolio and strengthens our ability to connect key steps in cell line development," said John Luck, President of Nova Biomedical's Biopharma Business. "By integrating cell sorting with clone isolation and high-confidence verification, alongside analytical control points such as cell culture monitoring and osmolality, we are enabling customers to reach a successful clone more quickly and generate insights that help optimize clone selection and drive better performance during process development, scale-up, and manufacturing. This is an important step in building a more connected and differentiated platform for cell line development and bioprocessing."

About Nova Biomedical
Nova Biomedical is a global provider of advanced analytical instruments and solutions for the biopharmaceutical and clinical markets. The company's portfolio supports critical workflows across cell line development, process development, and manufacturing, enabling customers to improve productivity, quality, and operational efficiency.

About NanoCellect
NanoCellect develops microfluidic cell sorting technologies designed for gentle, sterile cell isolation. Its platforms are used in applications including cell line development, single-cell analysis, and cell therapy research.

Lisa Fahey

VP, Corporate Programs and Communications

Email: lfahey@novabio.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/nova-biomedical-advances-integrated-cell-line-development-workflows-nanocellect-products-are-now-part-of-nova-biomedical-302834176.html

rt.gif?NewsItemId=EN11725&Transmission_Id=202607240955PR_NEWS_EURO_ND__EN11725&DateId=20260724


24.07.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2371474  24.07.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer